← All trials
NCT04670601
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 19, 2018
- Primary completion
- Jul 15, 2018
- Completion date
- Jul 15, 2018
- First posted
- Dec 17, 2020
- Last posted
- Dec 17, 2020
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AngeliniLead sponsor
- Cross Research S.A.Overall official - principal investigator
- Cross Research S.A.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.